
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
The treatment of epilepsy in developing countries: where do we go from here?

Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent noncommunicable diseases. As the understanding of its physical and social burden has increased it has moved higher up the world health agenda. Over four-fifths of the 50 million people with epilepsy are thought to be in developing countries; much of this condition results from preventable causes. Around 90% of people with epilepsy in developing countries are not receiving appropriate treatment. Consequently, people with epilepsy continue to be stigmatized and have a lower quality of life than people with other chronic illnesses. However, bridging the treatment gap and reducing the burden of epilepsy is not straightforward and faces many constraints. Cultural attitudes, a lack of prioritization, poor health system infrastructure, and inadequate supplies of antiepileptic drugs all conspire to hinder appropriate treatment. Nevertheless, there have been successful attempts to provide treatment, which have shown the importance of community-based approaches and also indicate that provision for sustained intervention over the long term is necessary in any treatment programme. Approaches being adopted in the demonstration projects of the Global Campaign Against Epilepsy--implemented by the International League Against Epilepsy, the International Bureau for Epilepsy, and the World Health Organization--may provide further advances. Much remains to be done but it is hoped that current efforts will lead to better treatment of people with epilepsy in developing countries.
- University College London United Kingdom
Malawi, Anticonvulsants/supply and distribution, cost of illness, India, phenobarbital, World Health Organization, Epilepsy/epidemiology, Developing countries, Clinical Protocols, Cost of Illness, Humans, clinical protocols, Developing Countries, Epilepsy, Health Priorities, Clinical protocols, Health Policy, developing countries, sustainability, Kenya, Sustainability, Phenobarbital, anticonvulsants, Cost of illness, epilepsy, Anticonvulsants, Phenobarbital/therapeutic use, Public aspects of medicine, RA1-1270, Epilepsy/drug therapy
Malawi, Anticonvulsants/supply and distribution, cost of illness, India, phenobarbital, World Health Organization, Epilepsy/epidemiology, Developing countries, Clinical Protocols, Cost of Illness, Humans, clinical protocols, Developing Countries, Epilepsy, Health Priorities, Clinical protocols, Health Policy, developing countries, sustainability, Kenya, Sustainability, Phenobarbital, anticonvulsants, Cost of illness, epilepsy, Anticonvulsants, Phenobarbital/therapeutic use, Public aspects of medicine, RA1-1270, Epilepsy/drug therapy
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).195 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
